Biomedical subjects

A G Gorbachev

Publications and source records attributed to A G Gorbachev.

23 records · Page 2Linked to original sources

PubMedDate not supplied

[The immune status of patients with primary and secondary chronic pyelonephritis].

Immunological examination (T- and B-cell immunity, metabolic activity of phagocytes) was conducted in 10 patients with primary and 21 patients with secondary chronic pyelonephritis in the phase of latent inflammation resistant to conventional antibacterial therapy versus 12 patients free of this disease. It was found that immunoreactivity in the above patients was compromised as shown by quantitative and qualitative deficiency of T-cell immunity (a fall in the absolute number of CD3+, absolute and relative content of CD2+DR+, changed proportion of T-lymphocyte subpopulations, low activity of oxygen-dependent anti-infection systems of phagocytes). B-system immunity did not much change for the worse. In primary chronic pyelonephritis immunoreactivity was affected more seriously.

Adolescent↗

PubMedDate not supplied

[Effect of a renal peptide complex on experimental acute pyelonephritis].

The purpose of the present study was to examine the effects of the animal renal peptide complex renaline obtained via acid extraction on the cause of acute pyelonephritis in the experiment. Renaline was found to be highly effective in treating experimental acute pyelonephritis in rats. This is manifested as improved changes in the parameters of leukocytosis, leukocyturia, rectal temperatures, and bacteriuria along with the regression of abnormal changes and the reduction in renal mass differences, as compared to the similar parameters in untreated animals. The findings indicate that the clinical use of renaline in the combined therapy for acute pyelonephritis.

Acute Disease↗

PubMedDate not supplied

[Effectiveness of prostatylene in the prevention of decompression disease in an experiment].

Works done under elevated environmental pressures present a risk for decompression disease. The use of altitude chambers for its prevention and treatment is technically complex and expensive. The paper presents the results of studies into the effects of the new peptide regulator prostatylene isolated from the bovine prostate. Experiments were conducted on 132 albino noninbred male rats weighing 180-220 g. All the rats were divided into 10 groups by the dose (from 0.5 to 5.0 mg/kg) and frequency of prostatylene administration (1-11 days). The agent was injected in a single intramuscular dose. Altitude exposure was made in a 75-liter chamber provided by a chemical absorbent container. Air temperatures were constant (19-21 degrees C) humidity was no higher than 75%. A compressor was used to pump as high as 0.7 MPa. The duration of compression, isopression, and decompression was 3 min, 1 hour, and 80 sec, respectively. The percentage of rat deaths and the interval from the termination of decompression to death were used as an index for the efficacy of prostatylene. The preset altitude exposure led to 75% death in control rats. A single dose of prostatylene did not affect this index, but thrice preinjection of the agent showed as high as 25% animal death reductions. Its protective properties were shown when the agent was administered in a dose 1 mg/kg for 5 days. It is concluded that the prostate participates in the formation of nonspecific mechanisms of defense when the body is influenced by environmental factors and that prostatic peptides are able to prevent decompression disease in the experiment.

Animals↗

PubMedDate not supplied

[The effect of prostatilen on the hemostatic indices in chronic prostatitis (a clinical and experimental study)].

Prostatilen effects on hemostasis were studied in 120 intact and 240 chronic prostatitis rats, 34 patients with chronic prostatitis. Intact rats responded to prostatilen by inhibition of platelet-vascular and coagulation hemostatic mechanisms and activation of fibrinolysis. Experimental chronic prostatitis in rats induced hemostatic shifts to hypercoagulation. These parameters returned to normal after 5- and 10-day course of prostatilen administration. A single prostatilen dose was unable to produce the above action. As to patients with chronic prostatitis, there were also prostatilen-induced platelet-vascular hemostatic normalization and fibrinolysis activation. Hemocoagulation was affected in a less degree. Prostatilen effects were unrelated to the disease stage. Normalization of hemostasis seems to be one of the factors of prostatilen therapeutic efficacy in chronic prostatitis. This peptide is found effective as a pathogenetic treatment of chronic prostatitis.

Animals↗

PubMedDate not supplied

[The bioregulatory therapy of patients with chronic pyelonephritis].

Prostatilen (5 mg/day i.m. for 5 days) was given to 46 patients with chronic pyelonephritis in the latent inflammation phase. The treatment resulted in relief of clinical symptoms, positive trend in laboratory indices characterizing activity of renal inflammation, albumin-globulin ratio. There was a decrease in leukocyturia, bacteriuria, ESR, blood fibrinogen and ceruloplasmin levels. Prostatilen reduced hypercoagulation and enhanced fibrinolytic activity of blood. The immunograms showed prostatilen-induced correction of immunity: T-lymphocyte count and functional activity increased, proportion of T-cell subpopulations returned to normal, metabolic activity of phagocyte oxygen-dependent substances became more intensive. The ability of prostatilen to initiate normalization of hemocoagulation and immunity is thought to be an essential factor of its therapeutic efficacy in chronic pyelonephritis.

Adjuvants, Immunologic↗